secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001628280-25-035135
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20
--------------------------------------------------------------------------------

- GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
- Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.
- Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.
- Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.
- Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/0001628280-25-035135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/abt-20250717.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-035135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer